Format

Send to

Choose Destination
J Am Acad Dermatol. 2007 Jan;56(1):148-53. Epub 2006 Sep 6.

Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases.

Author information

1
Department of Dermatology, St Vincent's Hospital, Melbourne, Australia.

Abstract

Three patients suffering from classic dermatomyositis (juvenile and adult-onset) with prominent recalcitrant skin manifestations are described. All patients demonstrated good control of muscle symptoms on immunosuppressive medications, but their cutaneous disease persisted despite treatment with at least 4 different systemic treatments and topical agents. They were given rituximab, a monoclonal anti-CD20 antibody, achieving a response with minimal side effects. We document our experience with this medication for the cutaneous lesions of dermatomyositis.

PMID:
17097377
DOI:
10.1016/j.jaad.2006.05.068
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center